Tarsus Pharmaceuticalsincis A Biopharmaceutical Company Based In Irvinecaliforniafocused On Developing And Commercializing Innovative Therapies In Eye Care And Infectious Disease Preventionthe Company Is Publicly Traded Under The Ticker Symbol Xdemvytarsus Is Dedicated To Addressing Significant Diseases With Limited Treatment Options By Leveraging Proven Science And New Technology The Flagship Productxdemvya Lotilaner Ophthalmic Solution0 25 Is The First Fda Approved Treatment For Demodex Blepharitisproviding Relief To Patients Suffering From This Eyelid Conditiontarsus Is Also Advancing A Robust Pipeline Of Drug Candidates Targeting Various Diseasesincluding Ocular Rosacealyme Disease Preventionand Malaria Reductiontheir Commitment To Addressing Unmet Medical Needs Is Reflected In Their Patient Centric Approach And Engagement With Healthcare Providers And The Medical Community
